



31 October, 2013

Company Announcements Office
Australian Securities Exchange

Nanosonics earns top honour at AusBiotech awards

Nanosonics Limited (ASX: NAN) is pleased to announce it has been named the healthcare industry's Company of the Year for 2013.

The Janssen 2013 Industry Excellence Awards recognise outstanding commercialisation of innovative healthcare solutions by Australian biotechnology and healthcare companies. The award was presented at the opening reception of the AusBiotech National Conference in Brisbane last night.

Nanosonics' develops easy-to-use, environmentally friendly and quality assured products for the infection control market. The company's first product, the trophon[®] EPR, delivers high level disinfection to intra-cavity ultrasound probes, replacing the current practice of manual disinfection by toxic chemicals.

The award committee, comprising members of Janssen and AusBiotech, the industry's peak representative body, measures companies against a series of criteria demonstrating significant achievements in the past 12 months. These include new business deals, product pipeline, intellectual property, company strategy and revenue.

Nanosonics Chief Executive Officer Michael Kavanagh said it was an honour for the organisation's achievements over the past few years to be formally recognised.

"Infection control is of major importance to global healthcare, which is why the novel trophon[®] EPR system was introduced to deliver superior high level disinfection for intra-cavity ultrasound probes," Mr Kavanagh said.

"Not only does the trophon[®] EPR deliver exceptional results, it does so in a more cost-effective, safe and environmentally-friendly way, therefore eliminating the need for the use of toxic chemicals. As we expand our reach globally, this innovative system is quickly establishing itself as the new standard of care in high level disinfection."

The committee noted Healthcare Acquired Infections were an area of high unmet clinical need.

"Australia is one of the world's thriving biotechnology hubs and we are constantly impressed by the quality and quantity of local innovation year after year," Janssen-Cilag Managing Director Chris Hourigan said.

"All the winners of this year's awards have demonstrated an unswerving commitment to innovation in healthcare and represent the spirit of collaboration and commercial savvy required to be successful in this space."

Michael Kavanagh
CEO



For more information please contact:

Michael Kavanagh, CEO or McGregor Grant, CFO, on 02 8063 1600

Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722 / boliver@buchanwe.com.au

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au